BR112021022156A2 - Peptídeo de bnip3 para tratamento de lesão de reperfusão, seu uso, composição farmacêutica, e método para rastreamento de um composto adequado para prevenção de lesão de reperfusão - Google Patents

Peptídeo de bnip3 para tratamento de lesão de reperfusão, seu uso, composição farmacêutica, e método para rastreamento de um composto adequado para prevenção de lesão de reperfusão

Info

Publication number
BR112021022156A2
BR112021022156A2 BR112021022156A BR112021022156A BR112021022156A2 BR 112021022156 A2 BR112021022156 A2 BR 112021022156A2 BR 112021022156 A BR112021022156 A BR 112021022156A BR 112021022156 A BR112021022156 A BR 112021022156A BR 112021022156 A2 BR112021022156 A2 BR 112021022156A2
Authority
BR
Brazil
Prior art keywords
reperfusion injury
bnip3
treatment
peptide
screening
Prior art date
Application number
BR112021022156A
Other languages
English (en)
Inventor
Tienush Rassaf
Ulrike Hendgen-Cotta
Original Assignee
Bimyo GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bimyo GmbH filed Critical Bimyo GmbH
Publication of BR112021022156A2 publication Critical patent/BR112021022156A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7019—Ischaemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7038—Hypoxia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

peptídeos de bnip3 para o tratamento de lesão de reperfusão. a presente invenção refere-se a peptídeos capazes de inibir a atividade individual e a comunicação entre as vias de bnip3, bax e mitocôndrias. os peptídeos podem ser usados em métodos de tratamento de uma doença ou condição em um indivíduo no qual é desejável prevenir o dano celular e a morte celular.
BR112021022156A 2019-05-10 2020-05-08 Peptídeo de bnip3 para tratamento de lesão de reperfusão, seu uso, composição farmacêutica, e método para rastreamento de um composto adequado para prevenção de lesão de reperfusão BR112021022156A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19173715 2019-05-10
PCT/EP2020/062926 WO2020229362A1 (en) 2019-05-10 2020-05-08 Bnip3 peptides for treatment of reperfusion injury

Publications (1)

Publication Number Publication Date
BR112021022156A2 true BR112021022156A2 (pt) 2021-12-21

Family

ID=66483874

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021022156A BR112021022156A2 (pt) 2019-05-10 2020-05-08 Peptídeo de bnip3 para tratamento de lesão de reperfusão, seu uso, composição farmacêutica, e método para rastreamento de um composto adequado para prevenção de lesão de reperfusão

Country Status (15)

Country Link
US (1) US20220220174A1 (pt)
EP (1) EP3966230A1 (pt)
JP (1) JP2022532092A (pt)
KR (1) KR20220007084A (pt)
CN (1) CN114026114A (pt)
AU (1) AU2020275076A1 (pt)
BR (1) BR112021022156A2 (pt)
CA (1) CA3138825A1 (pt)
CO (1) CO2021015130A2 (pt)
CU (1) CU20210092A7 (pt)
EA (1) EA202192970A1 (pt)
IL (1) IL287946A (pt)
MX (1) MX2021013510A (pt)
SG (1) SG11202112252UA (pt)
WO (1) WO2020229362A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112608972B (zh) * 2020-12-21 2021-09-10 广东源心再生医学有限公司 Myog基因作为靶点在制备治疗心肌细胞凋亡相关的心血管疾病的药物中的应用
EP4333830A1 (en) * 2021-05-04 2024-03-13 Corvitus GmbH Method for inhibiting reperfusion injury
WO2023079141A2 (en) 2021-11-05 2023-05-11 Tienush Rassaf Amelioration and treatment of infarction damage

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2838444B1 (fr) * 2002-04-10 2016-01-01 Neovacs Nouveaux peptides et leur application en therapeutique
AU2003256636A1 (en) * 2002-07-22 2004-02-09 University Of Miami Preventing ischemia-induced cell damage
EP2072527A1 (en) * 2007-12-21 2009-06-24 Altonabiotec AG Fusion polypeptides comprising a SHBG dimerization component and uses thereof
US20130196922A1 (en) * 2010-07-21 2013-08-01 University Of Manitoba Bnip3 isoforms and methods of use

Also Published As

Publication number Publication date
AU2020275076A1 (en) 2021-11-25
MX2021013510A (es) 2022-02-11
US20220220174A1 (en) 2022-07-14
JP2022532092A (ja) 2022-07-13
CA3138825A1 (en) 2020-11-19
CU20210092A7 (es) 2022-06-06
EA202192970A1 (ru) 2022-03-03
SG11202112252UA (en) 2021-12-30
CN114026114A (zh) 2022-02-08
EP3966230A1 (en) 2022-03-16
CO2021015130A2 (es) 2021-11-30
KR20220007084A (ko) 2022-01-18
WO2020229362A1 (en) 2020-11-19
IL287946A (en) 2022-01-01

Similar Documents

Publication Publication Date Title
BR112021022156A2 (pt) Peptídeo de bnip3 para tratamento de lesão de reperfusão, seu uso, composição farmacêutica, e método para rastreamento de um composto adequado para prevenção de lesão de reperfusão
BR112022008858A2 (pt) Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer
ECSP20069418A (es) Compuestos heterocíclicos como inmunomoduladores
DOP2023000169A (es) Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos
CO2022002630A2 (es) Compuestos inhibidores de rip1 y métodos para hacer y utilizar los mismos
BR112022004248A2 (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para inibir a atividade de prmt5 em uma célula, e, método para o tratamento de câncer
ECSP20077518A (es) Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
BR112015004997A2 (pt) composições contendo misturas de alcanos semifluorados
BR112019002576A2 (pt) composto, medicamento¸ métodos para inibição de gcn2 em um mamífero e para a profilaxia ou tratamento de câncer em um mamífero, e, uso do composto ou um sal do mesmo
ECSP22076856A (es) Inhibidores de rip1k
BR112015020235A2 (pt) fragmento biologicamente ativo de proteína csf-1 ou um seu homólogo, ácido nucléico, proteína de fusão, ácido nucléico isolado, vetor, célula hospedeira, método de realização da proteína de fusão do primeiro aspeto da invenção, composição, utilização de uma proteína de fusão, método de tratamento para um indivíduo sofrendo de cancro do fígado e que irá ser submetido a cirurgia, método de tratamento para um indivíduo que irá ser submetido a cirurgia de transplante de fígado, e, kit
DOP2022000042A (es) Compuestos inhibidores de rip1 y métodos para prepararlos y usarlos
CO2023000051A2 (es) Inhibidores de rip1k
BR112018073553A2 (pt) medicamento e composição farmacêutica para a prevenção ou tratamento de fibromialgia ou sintomas funcionais associados com fibromialgia, método para prevenir ou tratar fibromialgia ou sintomas funcionais associados com fibromialgia em um indivíduo, e, uso de um composto carbamato.
CL2021000129A1 (es) Apirasas solubilizadas, métodos y usos
BR112018069168A2 (pt) agonistas de cd31shed para uso na prevenção e/ou tratamento de lesão por reperfusão
BR112018070929A2 (pt) peptídeos bioativos peguilados e seu uso
EA201992587A1 (ru) Пептиды и их применение в качестве противовирусных агентов
AR120412A1 (es) Compuestos heterocíclicos inhibidores de rip1
CO2023012077A2 (es) Inhibidores heterocíclicos de la cinasa rip1
BR112015021448A2 (pt) kits e métodos para o tratamento de câncer utilizando peptídeos gliadina
BR112022025191A2 (pt) Compostos de imidazopiridazina com atividade de inibidores de alk2
BR112019021330A2 (pt) Métodos e compostos terapêuticos.
BR112017017064A8 (pt) “composição farmacêutica para prevenir ou tratar câncer, e uso do composto de fórmula i”